Home  /   Products  /   Musculoskeletal system  /   Glucosamine (Sustaguard artro) intramuscular 200 mg/ml 2 ml – [5 ampoules]

Glucosamine (Sustaguard artro) intramuscular 200 mg/ml 2 ml – [5 ampoules]


A drug that affects the metabolism in cartilage tissue. Stimulator of proteoglycan biosynthesis

SKU: 62856 Category:


Sustagard Arthro Pharmacodynamics
The drug stimulates the regeneration of cartilage tissue, has anabolic, anti-catabolic, chondroprotective, anti-inflammatory, analgesic effects.
Glucosamine sulfate, the active ingredient of the product SUSTAGARD® ARTRO, is a salt of the natural aminonosaccharide glucosamine, which is physiologically present in the body. Glucosamine stimulates the synthesis of proteoglycans (glucosaminoglycans and hyaluronic acid) of synovial fluid by chondrocytes; it inhibits enzymes (collagenase, phospholipase A2, etc.) that cause destruction of synovial fluid. ), causing destruction of cartilage tissue, prevents the formation of superoxide radicals, inhibits the activity of lysosomal enzymes, initiates the process of sulfur fixation in the synthesis of chondroitinic acid and promotes normal deposition of calcium in bone tissue, prevents the damaging effects of corticosteroids on chondrocytes and disruption of glycosaminoglycan synthesis, induced by nonsteroidal anti-inflammatory drugs.
Sulfogroups are also involved in the synthesis of glycosaminoglycans and cartilage metabolism, and sulfoesters of the side chains in proteoglycans, contributing to water retention – in maintaining the elasticity of the cartilage matrix.
Glucosamine sulfate stops cartilage destruction and reduces symptoms in osteoarthritis. Reduction of clinical symptoms is usually evident in 2 weeks from the start of treatment with clinical improvement maintained for 8 weeks after discontinuation of the drug.


Primary and secondary osteoarthritis, osteochondrosis, spondyloarthritis.


Contraindications .
Hypersensitivity to glucosamine, lidocaine and other components of the preparation SUSTAGARD® ARTRO.
Because of lidocaine content: cardiac conduction disorders, acute cardiac insufficiency, history of epileptiform convulsions, severe liver and renal function disorders; pregnancy and lactation, children and adolescents below 18 years of age.
Patients with chronic heart failure, arterial hypotension should use the drug with caution.
If intolerance of seafood (shrimp, shellfish) increases the likelihood of allergic reactions to the drug.
Safety of using anesthetics of lidocaine group is doubtful in patients prone to malignant hyperthermia, therefore in such cases their use should be avoided. Particular caution should be exercised when using the drug in patients with circulatory insufficiency, arterial hypotension, hepatic and/or nocicular dysfunction. Caution should be exercised when prescribing lidocaine to elderly patients, patients with epilepsy, patients with impaired cardiac conduction and patients with respiratory insufficiency.


Dosage and administration


  • Only for intramuscular use! The drug is not intended for intravenous administration.
  • Immediately before introduction, mix the contents of ampoule A with ampoule B (solvent) in one syringe. Prepared solution (3 ml) is injected intramuscularly 3 times a week for 4-6 weeks.
  • Injections of the drug can be combined with ingestion of glucosamine.